NG-350A has received FDA fast track designation for mismatch repair-proficient locally advanced rectal cancer, addressing a ...
KEYTRUDA Plus LENVIMA Demonstrates Durable 5-Year Survival Benefit Vs Chemotherapy for Patients With Advanced Endometrial ...
Merck (MRK) and Eisai (ESAIY) announced long-term follow-up data continued to show durable benefit of KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine ...
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the expansion of its Phase III ...
FDA fast track designation for NG-350A aims to expedite its development for mismatch repair-proficient locally advanced ...
Dr. Praveen Vikas, Dr. Tyler Johnson, and Dr. Russell Broaddus present the ASCO endorsement of the Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ...
Three presentations at ESMO 2025 will demonstrate Lunit SCOPE IO’s value in predicting immunotherapy response in colorectal, ...
Prof David Kerr discusses a recent study investigating tumor mutational burden as a potential contributing factor to ...
Results showed a DFS benefit with the addition of pembrolizumab to chemotherapy for patients with mismatch repair-deficient tumors. The rate of grade 3 or greater adverse events was slightly higher ...
Clinicopathologic and Molecular Analysis of Normal Karyotype Therapy-Related and De Novo Acute Myeloid Leukemia: A Multi-Institutional Study by the Bone Marrow Pathology Group The Lynch syndrome ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback